secwatch.observer — SEC 8-K summary
======================================

Issuer:     bioAffinity Technologies, Inc. (BIAF)
CIK:        0001712762
Form:       8-K
Filed at:   2026-09-01T20:30:23+00:00
Accession:  0001493152-26-041020
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

bioAffinity advances CyPath Lung for surveillance of lung cancer survivors
--------------------------------------------------------------------------

- Announces potential use of CyPath Lung for post-treatment surveillance; >680,000 Americans living with prior lung cancer diagnosis.
- NSCLC recurrence after curative treatment runs 20-55%; ASCO recommends imaging every 6 months for 2 years.
- CyPath Lung detection trial: 92% sensitivity, 87% specificity, 88% accuracy, 99% NPV; not yet validated for surveillance.
- Company cites 3 years of commercial experience and case studies supporting risk stratification of challenging nodules.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041020/0001493152-26-041020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1712762/000149315226041020/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-041020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer